Design Therapeutics Inc

DSGN

Company Profile

  • Business description

    Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

  • Contact

    6005 Hidden Valley Road
    Suite 110
    CarlsbadCA92011
    USA

    T: +1 858 293-4900

    https://www.designtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    56

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,841.0069.000.79%
CAC 407,662.593.32-0.04%
DAX 4023,673.29236.32-0.99%
Dow JONES (US)44,494.94400.170.91%
FTSE 1008,785.3324.370.28%
HKSE24,186.73114.450.48%
NASDAQ20,202.89166.84-0.82%
Nikkei 22539,780.77205.56-0.51%
NZX 50 Index12,784.2949.760.39%
S&P 5006,198.016.94-0.11%
S&P/ASX 2008,610.4069.300.81%
SSE Composite Index3,454.213.54-0.10%

Market Movers